Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Net Margin of 461.48% for Q1 2026, down 101.33% on a QoQ basis from 34723.87% in Q4 2025, and down 46150.0% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Net Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 461.48% for Q1 2026.
- Quarterly Net Margin fell 46150.0% year-over-year to 461.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95.44% (down 8482.0% YoY) and the FY2025 annual result came in at 30.16%, up 4988.0% from the prior year.
- Net Margin was 461.48% for Q1 2026 at Biocryst Pharmaceuticals, down from 34723.87% in the prior quarter.
- Across five years, Net Margin topped out at 34723.87% in Q4 2025 and bottomed at 461.48% in Q1 2026.
- A 5-year average of 1972.38% and a median of 41.67% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2025 — Net Margin soared 3474424 bps — and 2026, when it sank 46150 bps.
- Biocryst Pharmaceuticals' Net Margin stood at 89.94% in 2022, then gained by 27 bps to 66.09% in 2023, then soared by 69 bps to 20.37% in 2024, then surged by 170556 bps to 34723.87% in 2025, then slumped by 101 bps to 461.48% in 2026.
- Business Quant data shows BCRX's Net Margin at 461.48% in Q1 2026, 34723.87% in Q4 2025, and 8.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -461.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.48% |
| Dec 31, 2025 | 34,723.87% |
| Sep 30, 2025 | 8.09% |
| Jun 30, 2025 | 3.11% |
| Mar 31, 2025 | 0.02% |
| Dec 31, 2024 | -20.37% |
| Sep 30, 2024 | -11.99% |
| Jun 30, 2024 | -11.59% |
| Mar 31, 2024 | -38.14% |
| Dec 31, 2023 | -66.09% |
| Sep 30, 2023 | -41.67% |
| Jun 30, 2023 | -91.31% |
| Mar 31, 2023 | -77.54% |
| Dec 31, 2022 | -89.94% |
| Sep 30, 2022 | -56.08% |
| Jun 30, 2022 | -89.82% |
| Mar 31, 2022 | -148.62% |
| Dec 31, 2021 | -37.70% |
| Sep 30, 2021 | -143.44% |
| Jun 30, 2021 | -86.47% |